Heart failure & cardiomyopathies
Semaglutide in heart failure and preserved ejection fraction (HFpEF) across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
Authors' conclusion
In participants with obesity phenotype of HFpEF, semaglutide improved symptoms, physical limitations and exercise function and reduced inflammation and body weight across obesity categories. In semaglutide-treated patients, the magnitude of benefit was directly related to the extent of weight loss.
Study context
- Population
- Patients with obesity phenotype of HFpEF
- Comparison
- Semaglutide vs placebo across obesity classes and by body weight reduction
- Primary endpoint
- Dual primary endpoints: change in KCCQ-CSS and body weight, across obesity classes I-III and by body weight reduction with semaglutide
- Follow-up
- 52 weeks
Primary result
As reported in the abstract
- Semaglutide consistently improved all outcomes across obesity categories
- P for treatment effects × body mass index (BMI) interactions = not significant for all
Secondary outcomes
Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) improvement per 10% body weight reduction (semaglutide-treated)
- Improvement in KCCQ-CSS for each 10% body weight reduction, points
- 6.4 (95% CI 4.1, 8.8)
- Greater improvements with larger body weight reduction
6MWD improvement per 10% body weight reduction (semaglutide-treated)
- Improvement in 6MWD for each 10% body weight reduction, m
- 14.4 (95% CI 5.5, 23.3)
C-reactive protein (CRP) by body weight reduction (semaglutide-treated)
- Improvement in CRP greater with larger body weight reduction
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →